亚太药业(002370) - 2025 Q1 - 季度财报

Revenue and Profitability - The company's revenue for Q1 2025 was ¥64,550,537.91, a decrease of 42.73% compared to ¥112,712,517.95 in the same period last year[4] - The net loss attributable to shareholders was ¥7,803,212.71, representing a 160.25% increase in losses from ¥2,998,386.71 year-on-year[4] - Total operating revenue decreased to ¥64,550,537.91 from ¥112,712,517.95, representing a decline of approximately 42.6% year-over-year[19] - Net profit for the period was a loss of ¥7,803,212.71, compared to a loss of ¥2,998,386.71 in the previous period, indicating a worsening of approximately 160.0%[20] - Basic and diluted earnings per share were both -0.0105, compared to -0.0049 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 50.56% to ¥11,574,799.13, up from ¥7,687,843.33 in the previous year[9] - Operating cash flow for the current period is ¥11,574,799.13, an increase of 50.5% compared to ¥7,687,843.33 in the previous period[22] - Total cash inflow from operating activities is ¥55,181,607.33, down 26.1% from ¥74,641,811.47 in the previous period[22] - Cash outflow from operating activities decreased to ¥43,606,808.20, a reduction of 34.8% from ¥66,953,968.14 in the previous period[22] - Cash and cash equivalents increased by ¥43,164,490.53, contrasting with a decrease of -¥57,104,256.47 in the previous period[23] - The ending balance of cash and cash equivalents is ¥762,863,213.79, up from ¥663,138,268.39 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,441,050,141.05, reflecting a 2.80% increase from ¥1,401,768,368.44 at the end of the previous year[4] - The company’s total liabilities increased significantly, with other payables rising by 155.20% to ¥48,882,214.68, compared to ¥19,154,466.61 last year[7] - Total liabilities increased to ¥443,188,946.04 from ¥429,587,364.82, marking an increase of approximately 3.0%[18] - Non-current assets totaled ¥436,421,017.37, down from ¥446,607,979.12, a decrease of about 2.4%[18] - The company’s total current assets amounted to RMB 1,004,629,123.68, up from RMB 955,160,389.32[16] Investment and Financing Activities - The company experienced a 98.01% increase in receivables financing, reaching ¥32,410,018.25, compared to ¥16,367,501.71 last year[7] - The company’s investment activities generated a net cash flow of ¥31,836,191.41, a significant increase from a negative cash flow of ¥2,890,338 in the previous year, marking a 1201.47% change[9] - Cash received from the disposal of subsidiaries and other business units is ¥30,000,000.00[23] - Cash paid for the purchase of fixed assets and intangible assets is ¥417,454.00, down from ¥2,890,338.00 in the previous period[23] - The company plans to apply for a credit limit of up to RMB 150 million from Agricultural Bank of China and RMB 30 million from Ningbo Bank[15] Operational Efficiency and Cost Management - The company is focusing on improving operational efficiency and reducing costs in response to declining revenues[19] - Total operating costs decreased to ¥70,881,335.56 from ¥114,454,069.55, a reduction of about 38.0% year-over-year[19] - The company reported a significant increase in research and development expenses, totaling ¥2,114,765.79, compared to ¥4,643,430.60 in the previous period, a decrease of approximately 54.5%[19] - The company has frozen funds of RMB 12,076,000 due to a legal dispute, while other funds totaling RMB 398,540,300 have been transferred to operational accounts[13] - The company has completed the cancellation of several fundraising accounts, with only one account remaining frozen[13] Shareholder Information - The company has a total of 745,667,530 shares outstanding, with 209,173,074 shares converted from convertible bonds[13] - The first quarter report has not been audited[24]